|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.16 EUR | +1.69% |
|
-1.01% | -2.30% |
| Jun. 05 | Study: Bayer's Finerenone slows progression of chronic kidney disease | RE |
| Jun. 05 | Bayer Announces Phase III FIND-CKD Results For KERENDIA In Non-Diabetic Chronic Kidney Disease | CI |
Evolution of the Average Target: Bayer AG
Evolution of the Target Price: Bayer AG
Changes in Analyst Recommendations: Bayer AG
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +36.82% | |||||
| +7.4% | |||||
| +8.63% | |||||
| +11.58% | |||||
| +10.29% | |||||
| +19.45% | |||||
| +4.53% | |||||
| +9.84% | |||||
| +0.76% | |||||
| +22.2% | |||||
| Average | +13.15% | |||||
| Weighted average by Cap. | +9.96% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| UBS | Matthew Weston |
| AlphaValue/Baader Europe | |
| JEFFERIES | Michael Leuchten |
| DZ BANK | Peter Spengler |
| BARCLAYS | Charles Pitman-King |
| JPMORGAN | Richard Vosser |
| alphavalue | Abhishek Raval |
| Rothschild & Co Redburn | |
| GOLDMAN SACHS | James Quigley |
| ODDO BHF | |
| BERENBERG | Sebastian Bray |
| Morningstar | |
| MWB Research | |
| BANK OF AMERICA (BOFA) | Sachin Jain |
| BERNSTEIN RESEARCH | Florent Cespedes |
| Baptista Research | |
| HSBC | |
| DEUTSCHE BANK RESEARCH | Falko Friedrichs |
| STIFEL | Andreas Heine |
| Stifel Nicolaus | |
| MORGAN STANLEY | Thibault Boutherin |
| CREDIT SUISSE | Dominic Lunn |
| DEUTSCHE BANK | Falko Friedrichs |
| NORDLB | Thorsten Strauß |
| KEPLER CHEUVREUX | Christian Faitz |
| WARBURG RESEARCH | Ulrich Huwald |
| BRYAN GARNIER | Jean-Jaques Le Fur |
| INDEPENDENT RESEARCH | Tobias Gottschalt |
| BAADER BANK | Markus Mayer |
| LIBERUM CAPITAL | Graham Doyle |
| SOCIETE GENERALE (SOCGEN) | Florent Cespedes |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BAYN Stock
- Consensus Bayer AG
Select your edition
All financial news and data tailored to specific country editions
